Medical Condition News

RSS

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Physical activity may protect high-risk individuals from cognitive decline: Study

Physical activity promotes changes in the brain that may protect high-risk individuals against cognitive decline, including development of Alzheimer's disease, according to a new study done at the University of Wisconsin-Milwaukee (UWM).

19 Nov 2010

Research suggests new therapeutic approach to prevent transplant rejection

UCLA researchers have pinpointed the culprit behind chronic rejection of heart, lung and kidney transplants. Published in the Nov. 23 edition of Science Signaling, their findings suggest new therapeutic approaches for preventing transplant rejection and sabotaging cancer growth.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

Researchers document novel form of splicing in nerve cell cytoplasm

Cells have their own version of the cut-and-paste editing function called splicing. Researchers at the University of Pennsylvania School of Medicine have documented a novel form of splicing in the cytoplasm of a nerve cell, which dictates a special form of a potassium channel protein in the outer membrane.

19 Nov 2010

Personalised medicine could help develop effective treatments for serious diseases

Personalised medicine is a field that holds a lot of promise as a provider of practices and technology that could help develop more effective treatments for serious diseases such as cancer. Personalised medicine involves tailoring treatment according to the genetic profile and molecular makeup of each patient.

19 Nov 2010

African Americans have faster rates of decline in kidney function

African Americans along with some groups of Hispanics have faster rates of decline in kidney function compared to white Americans, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

19 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

International businessman donates $50,000 for SCCO cancer study

International businessman and philanthropist Foster Friess has donated $50,000 to help launch a study of small cell carcinoma of the ovary (SCCO) by the Translational Genomics Research Institute (TGen) and the Van Andel Research Institute (VARI).

19 Nov 2010

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

Patients undergoing plastic or reconstructive surgery should receive a risk assessment before their procedure to predict whether they'll develop potentially fatal blood clots in the legs or lungs, according to research at the University of Michigan Medical School. Researchers also found that 1 in 9 patients at highest risk based on that assessment will develop clots if not given clot-preventing medications after surgery.

19 Nov 2010

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Bristol-Myers Squibb Company and Pfizer today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy.

19 Nov 2010

Study compares effect on HT status in mid, late life on dementia risk

Compared to women never on hormone therapy, those taking hormone therapy only at midlife had a 26 percent decreased risk of dementia; while women taking HT only in late life had a 48 percent increased risk of dementia, according to Kaiser Permanente researchers.

19 Nov 2010

CINJ experts to comment on importance of blood donation

Every two seconds, there is someone in the United States in need of blood. According to the American Red Cross, 65 percent of the American population is eligible to donate blood, but only five percent actually do. In New Jersey only two and a half percent of eligible donors will donate, while nine out of ten New Jersey residents will need blood at least once in their lives.

19 Nov 2010

Study suggests pomegranate juice can ward-off complications in kidney disease patients

Studies in recent years have claimed multiple health benefits of pomegranate juice, including that it is a good source of antioxidants and lowers both cholesterol and blood pressure, especially in diabetic and hypertensive patients.

19 Nov 2010

Experts formulate research related to psychological adjustment and traumatic brain injury

Five U.S. federal agencies recently cosponsored a set of expert work groups to formulate common data elements for research related to psychological adjustment and traumatic brain injury (TBI).

19 Nov 2010

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

New University of Georgia research, published this week in the early online edition of the journal Proceedings of the National Academy of Sciences, has found that blocking the action of an enzyme called GnT-V significantly delays the onset and spread of tumors in mice with cancer very similar to many cases of human breast cancer.

19 Nov 2010

Genetic alterations may lead to thoracic aortic disease

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston (UTHealth).

19 Nov 2010

Doctors recommend drug holidays from bisphosphonates to enhance bone health

Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone.

19 Nov 2010

Medical Condition News

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Physical activity may protect high-risk individuals from cognitive decline: Study

Research suggests new therapeutic approach to prevent transplant rejection

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

ACE-041 drug may provide new option to treat cancer

Researchers document novel form of splicing in nerve cell cytoplasm

Personalised medicine could help develop effective treatments for serious diseases

African Americans have faster rates of decline in kidney function

DoD recommends funding for Synta's STA-9584 for prostate cancer study

International businessman donates $50,000 for SCCO cancer study

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

Bristol-Myers Squibb, Pfizer discontinue Phase 3 APPRAISE-2 trial in patients with ACS

Study compares effect on HT status in mid, late life on dementia risk

CINJ experts to comment on importance of blood donation

Study suggests pomegranate juice can ward-off complications in kidney disease patients

Experts formulate research related to psychological adjustment and traumatic brain injury

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

Genetic alterations may lead to thoracic aortic disease

Doctors recommend drug holidays from bisphosphonates to enhance bone health

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News